Carfilzomib Treatment Causes Molecular and Functional Alterations of Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes

BACKGROUND: Anticancer therapies have significantly improved patient outcomes; however, cardiac side effects from cancer therapies remain a significant challenge. Cardiotoxicity following treatment with proteasome inhibitors such as carfilzomib is known in clinical settings, but the underlying mecha...

Descripción completa

Detalles Bibliográficos
Autores principales: Forghani, Parvin, Rashid, Aysha, Sun, Fangxu, Liu, Rui, Li, Dong, Lee, Megan R., Hwang, Hyun, Maxwell, Joshua T., Mandawat, Anant, Wu, Ronghu, Salaita, Khalid, Xu, Chunhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075231/
https://www.ncbi.nlm.nih.gov/pubmed/34873922
http://dx.doi.org/10.1161/JAHA.121.022247

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075231/
https://www.ncbi.nlm.nih.gov/pubmed/34873922
http://dx.doi.org/10.1161/JAHA.121.022247

Ejemplares similares